

Haematologica
HAEMATOL/2018/192328
Version 4

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2

Paul M. Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Osnat Bairey, Nancy L. Bartlett, Jan A. Burger, Peter Hillmen, Steven Coutre, Stephen Devereux, Sebastian Grosicki, Helen McCarthy, Jianyong Li, David Simpson, Fritz Offner, Carol Moreno, Cathy Zhou, Lori Styles, Danelle James, Thomas J. Kipps, and Paolo Ghia

Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Barr reported a consultancy/advisory role for AbbVie, Celgene, Novartis, Seattle Genetics, Genentech, Verastem, Gilead and Merck. Dr Robak reported research funding from Pharmacyclics LLC, an AbbVie company. Dr Owen reported honoraria from Roche, Lundbeck, Gilead, Janssen, AbbVie, Celgene, Merck, and AstraZeneca; a consultancy/advisory role for Roche; and research funding from Gilead, Pharmacyclics LLC, an AbbVie Company, and Roche. Dr Tedeschi reported a consultancy/advisory role for Janssen and AbbVie; and honoraria from Janssen, AbbVie, Gilead, and Roche. Dr Bairey reported a consultancy/advisory role for AbbVie and research funding from Janssen. Dr Bartlett reported a consultancy/advisory role with Gilead. Dr Burger reported honoraria and travel expenses with Janssen, and a consulting/advisory role with Gilead, Pharmacyclics LLC, an AbbVie Company, and Janssen; and research funding from Pharmacyclics LLC, an AbbVie Company. Dr Hillmen reported honoraria, a consultancy/advisory role, and speakers' bureau for AbbVie, Janssen, Gilead, and Acerta; and research funding from AbbVie, Pharmacyclics LLC, an AbbVie Company, Janssen, Roche, GlaxoSmithKline, and Gilead. Dr Coutre reported a consultancy/advisory role for AbbVie, Gilead, Novartis, Celgene, Janssen, and Pharmacyclics LLC, an AbbVie Company; and research funding from AbbVie, Pharmacyclics LLC, an AbbVie Company, Gilead, Celgene, and Novartis. Dr Devereux reported honoraria and a consultancy/advisory role for Janssen, AbbVie, MSD, and Gilead; and speakers' bureau and travel expenses for Janssen and Gilead. Dr McCarthy reported honoraria and travel expenses from Roche, AbbVie, Novartis, and Janssen; and a consultancy/advisory role with Janssen. Dr Simpson reported honoraria from Roche, Janssen, Merck, and Celgene; and research funding from Amgen. Dr Moreno reported a consulting/advisory role with Janssen, AbbVie and Gilead; and research funding from Gilead and Roche. Cathy Zhou and Dr Styles reported employment and travel accommodations from Pharmacyclics LLC, an AbbVie Company, and stock ownership with AbbVie. Dr James reported employment with Pharmacyclics LLC, an AbbVie Company; spouse employment with AbbVie; stock ownership for self/husband with AbbVie; and patents/royalties/other intellectual property with AbbVie. Dr Kipps reported a consultancy/advisory role for AbbVie, Genentech, Gilead, Pharmacyclics LLC, an AbbVie company and Celgene; and research funding from AbbVie, Genentech, Roche, Pharmacyclics LLC, an AbbVie Company, and Oncternal. Dr Ghia reported a consultancy/advisory role for AbbVie, Adaptive, Gilead, Janssen, Pharmacyclics LLC, an AbbVie Company, and Roche; research funding from AbbVie, Gilead, Janssen, and Novartis; and speakers' bureau for Gilead. Dr Offner, Dr Grosicki and Dr Li reported no relevant financial disclosures.

Contributions: C.Z., L.S., and D.J. designed the study. P.M.B., C.O., A.T., O.B., N.B., J.A.B, P.H., S.C., S.D., S.G., H.M, J.L., D.S., F.O., C.M., T.J.K, and P.G. contributed to collecting the data with the other RESONATE-2 investigators and their research teams. All authors had full access to the data, were involved in data interpretation, and vouch for accuracy of the data. P.M.B., C.Z., L.S., and D.J. collaboratively wrote the first draft of the manuscript. All authors reviewed and revised the manuscript, provided final approval, and made the decision to submit the manuscript for publication. Medical writing support was provided by a professional medical writer and funded by the sponsor.